BioSpace News Archive

Deals

Advaxis and Ayala Merge to Hone In on Desmoid Tumors, Prostate Cancer

Advaxis and Ayala Pharmaceuticals entered a reverse merger deal to focus on two clinical-stage cancer therapies: AL102 for desmoid tumors and ADXS-504 for prostate cancer.

October 19, 2022
·
2 min read
·
Mark Terry
Business

Ambrx Drops Lead Asset, Cuts 15% of Staff in Strategic Reprioritization (Updated)

Ambrx Biopharma Inc. announced it will lay off 15% of its workforce and suspend development of its lead candidate in a strategic realignment initiative.

October 19, 2022
·
3 min read
·
Tristan Manalac
Business

PIC Closes $35M Series A to Advance Novel Breast Cancer Therapeutic (Updated)

Massachusetts-based PIC Therapeutics has closed a $35 million Series A financing round centered around the advancement of its lead asset, a novel therapeutic for advanced metastatic breast cancer.

October 19, 2022
·
2 min read
·
Rosemary Scott
Business

Pfizer, Merck and J&J Back UK Startup Mining the Dark Genome for Autoimmune Therapies

Backed by Pfizer, Merck KGaA and J&J, Nucleome Therapeutics secured £37.5 million (about $42.16 million) in an oversubscribed Series A financing round.

October 19, 2022
·
2 min read
·
Alex Keown
Business

Jazz Drops $50M for Exclusive Rights to Zymeworks’ Bispecific HER2 Hopeful

Jazz and Zymeworks entered into a $50 million licensing agreement over zanidatamab, Zymeworks’ bispecific antibody targeting HER2.

October 19, 2022
·
3 min read
·
Tristan Manalac
Drug Development

PTC Runs into Latest Huntington’s Roadblock with US Trial Pause (Updated)

A Phase II trial studying PTC Therapeutics’ PTC518 in Huntington’s disease has been paused in the United States following a request from the FDA for additional data.

October 19, 2022
·
2 min read
·
Kaley Lefevre
Drug Development

Gene Therapy could Change the Goalpost in Sickle Cell Disease

While worthy advances have recently been made in sickle cell disease, companies such as Graphite Bio, bluebird bio, Vertex Pharmaceuticals and Editas Medicine have loftier ambitions.

October 19, 2022
·
5 min read
·
Alex Keown
Nine-month results 2022 of Sartorius Stedim Biotech

Sartorius Stedim Biotech, a leading partner of the biopharma industry, closed the first nine months of 2022 with double-digit sales revenue and earnings growth and specified its outlook for the current fiscal year.

October 19, 2022
·
10 min read
Biotech Bay

Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research Into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022

Genentech, a member of the Roche Group, announced that new Ocrevus® data and continued research into neuromyelitis optica spectrum disorder will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis from October 26-28, 2022.

October 19, 2022
·
21 min read
BioCapital

Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences

Sirnaomics Ltd. announced that it will present the latest developments on GalAhead™, a GalNAc-RNAi therapeutic platform, and its pipeline programs, at two industry conferences in Boston: the RNA Leaders USA Congress and 18th Drug Discovery Innovation Programme.

October 19, 2022
·
2 min read